Traders should monitor for imminent ATM activity or follow-on offerings, especially given the company's clinical-stage status and lack of revenue. The combination of issuer and selling shareholder shelves increases supply pressure, which could weigh on share price. Watch for 424B filings indicating actual pricing and takedown of shares.
Price Chart
Executive Summary
Kalaris Therapeutics has two S-3 shelf registrations that became effective on April 13, 2026. The first allows the company to raise up to $350 million through various securities, including a $100 million ATM equity program, while the second permits selling stockholders to resell up to 5,000,000 shares. These effective shelves create a potential for significant shareholder dilution and indicate near-term capital raising needs.
Key Facts
- Two S-3 shelf registrations became effective on 2026-04-13
- First shelf (File No. 333-294883) allows Kalaris to offer up to $350 million in securities, including $100 million via ATM
- Second shelf (File No. 333-294881) allows resale of 5,000,000 shares by selling stockholders, including 4,200,000 existing shares and 800,000 shares from pre-funded warrants
- Company will not receive proceeds from the resale, except potentially $80 from warrant exercises
- Market cap is $145M, making the $350M potential raise highly dilutive
Financial Impact
Potential dilution from up to $350 million in new equity raises and immediate overhang from 5,000,000 resalable shares, representing significant dilution relative to current $145M market cap
Risk Factors
- Significant equity dilution from potential $350 million capital raise
- Near-term share price pressure from up to 5,000,000 resalable shares
- Low insider buying and minimal warrant proceeds suggest limited insider confidence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (KLRS) — Batch item 1 | 9999999995-26-001176 |
| Document: 9999999995-26-001176-index.html | 9999999995-26-001175 |
| Document: 9999999995-26-001176.txt | 9999999995-26-001176 |
| EFFECT Filing (KLRS) — Batch item 4 | 9999999995-26-001175 |
| Document: 9999999995-26-001175-index.html | 9999999995-26-001176 |
| Document: 9999999995-26-001175.txt | 9999999995-26-001176 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | $1.80 | awaiting T+60 | — | $1.80 (−0.00%) |
Aug 11, 2026 11w ago | 8-K | $3.97 | awaiting T+60 | — | $1.80 (−54.66%) |
Aug 11, 2026 11w ago | Press Release | $3.97 | awaiting T+60 | — | $1.80 (−54.66%) |
Aug 3, 2026 12w ago | 3 | $4.32 | awaiting T+60 | — | $1.80 (−58.33%) |
Jul 20, 2026 14w ago | 8-K | $4.00 $2.23 | ▼ −44.25% | ▼ −49.09% | $1.80 (−55.00%) |
Jul 17, 2026 14w ago | 8-K | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.80 (−58.90%) |
Jul 17, 2026 14w ago | Press Release | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.80 (−58.90%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.36 $3.90 | ▼ −10.55% | ▼ −14.95% | $1.80 (−58.72%) |
May 12, 2026 24w ago | 8-K | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.80 (−62.42%) |
May 12, 2026 24w ago | Press Release | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.80 (−62.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers